Psyence Group Inc. (PSYGF)

USD 0.01

(-33.33%)

Long Term Debt Summary of Psyence Group Inc.

  • Psyence Group Inc.'s latest annual long term debt in 2024 was 33.27 Thousand CAD , down 0.0% from previous year.
  • Psyence Group Inc.'s latest quarterly long term debt in 2024 FY was 33.27 Thousand CAD , down -26.13% from previous quarter.
  • Psyence Group Inc. reported annual long term debt of 45.04 Thousand CAD in 2023, down -14.74% from previous year.
  • Psyence Group Inc. reported annual long term debt of 52.82 Thousand CAD in 2022, up 96610.06% from previous year.
  • Psyence Group Inc. reported quarterly long term debt of 33.27 Thousand CAD for 2024 Q4, down 0.0% from previous quarter.
  • Psyence Group Inc. reported quarterly long term debt of 41.03 Thousand CAD for 2024 Q1, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Psyence Group Inc. (2024 - 2016)

Created with Highcharts 11.1.0YearsLong Term Debt2016201720182019202020212022202320240 USD20000 USD40000 USD60000 USD

Historical Annual Long Term Debt of Psyence Group Inc. (2024 - 2016)

Year Long Term Debt Long Term Debt Growth
2024 33.27 Thousand CAD 0.0%
2023 45.04 Thousand CAD -14.74%
2022 52.82 Thousand CAD 96610.06%
2021 54.62 CAD 0.0%
2020 - CAD 0.0%
2019 - CAD 0.0%
2018 - CAD 0.0%
2017 - CAD 0.0%
2016 - CAD 0.0%

Peer Long Term Debt Comparison of Psyence Group Inc.

Name Long Term Debt Long Term Debt Difference
AstraZeneca PLC 22.33 Billion USD 100.0%
Bristol-Myers Squibb Company PFD CONV 2 38.18 Billion USD 100.0%
CSPC Pharmaceutical Group Limited 107.05 Million USD 99.969%
Clarus Therapeutics Holdings, Inc. - USD -Infinity%
Novartis AG 20.03 Billion USD 100.0%
PT Kalbe Farma Tbk. 19.39 Million USD 99.828%